Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed localized Ewing's sarcoma or peripheral primitive neuroectodermal tumor (PNET) of the bone or soft tissues~  * Diagnostic biopsy of primary tumor within 30 days of study~* Paraspinal or bony skull tumors of extradural origin allowed~  * No intradural soft tissue tumors~* Askin's tumor of the chest wall allowed~  * Chest wall tumors with ipsilateral pleural effusions or ipsilateral pleural-based secondary tumor nodules allowed~ * No contralateral pleural effusions~* No metastatic disease or distant node involvement~  * One pulmonary or pleural nodule greater than 1 cm in diameter OR more than 1 nodule greater than 0.5 cm in diameter are considered pulmonary metastasis~ * Solitary lung nodules of 0.5-1 cm OR multiple nodules of 0.3-0.5 cm allowed unless biopsy positive for tumor~* Light microscopic appearance (hematoxylin and eosin stained) consistent with Ewing's sarcoma or peripheral PNET~* No immunohistochemical or ultrastructural evidence of rhabdomyosarcoma~* No esthesioneuroblastoma~* Clinically or pathologically involved regional lymph nodes allowed~* No CNS involvement~PATIENT CHARACTERISTICS:~Age:~* 50 and under at diagnosis~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~Renal:~* Creatinine normal for age~* Creatinine clearance or isotope glomerular filtration rate at least 75 mL/min~Cardiovascular:~* Shortening fraction at least 28% by echocardiography OR~* Ejection fraction at least 55% by radionuclide angiogram~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other prior malignancy except skin cancer diagnosed at least 5 years ago and currently in remission~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for skin cancer~* No concurrent sargramostim (GM-CSF)~* No concurrent pegfilgrastim~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy~Surgery:~* Prior complete or partial excision of primary tumor allowed

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Regimen A (Type: EXPERIMENTAL): Test the hypothesis that chemotherapy given every two weeks (Regimen B) will produce higher event-free survival. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks (four cycles on Regimen A. The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide, etoposide, MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (Surgery, Radiation Therapy, or a combination) will begin on Week 13 which will be after four cycles of chemotherapy.
- Regimen B (Type: EXPERIMENTAL): Conventional every-three-week chemotherapy for patients with Ewing sarcoma and related tumors. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks six cycles on Regimen B). The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide etoposide MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (surgery, Radiation Therapy, or a combination) will begin on Week 13, which will be after six cycles of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).